Download PDF

1. Company Snapshot

1.a. Company Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.


This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers.The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products.This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.


The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications.This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products.The company was formerly known as Diversified Mortgage Investors, Inc.


and changed its name to Danaher Corporation in 1984.Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Show Full description

1.b. Last Insights on DHR

Danaher Corporation faced negative drivers, including decreased stakes from various investment firms. Bartlett & CO. Wealth Management LLC, Border to Coast Pensions Partnership Ltd, and CCLA Investment Management reduced their holdings by 7.2%, 41.5%, and 14.2%, respectively. Additionally, the company reported Q1 earnings with a revenue miss and weak diagnostics. Cost pressures and FX headwinds are expected to impact performance. According to Marketbeat Ratings, the stock has a consensus rating of "Moderate Buy" from 23 analysts. Danaher reported Q1 sales of $5.95 billion, up 3.5% year-over-year.

1.c. Company Highlights

2. Danaher Drives Growth Amid Bioprocessing Surge

Danaher’s first‑quarter 2026 results paint a picture of disciplined growth and robust cash generation. Revenues climbed to $6.00 billion, a modest 0.5% uptick, while adjusted diluted net earnings per share rose 9.5% to $2.06, eclipsing the $1.94 consensus. Free cash flow surged to $1.10 billion, underscoring operational efficiency. With a P/E of 37.33 and a P/B of 2.6, the market is pricing in continued margin expansion and the upside from the upcoming Masimo deal.

Publication Date: Apr -22

📋 Highlights
  • Strong Earnings Growth: Adjusted diluted EPS rose 9.5% YoY to $2.06, driven by $1.1 billion in free cash flow.
  • Biotechnology Segment Outperforms: Core revenue surged 7% YoY, fueled by high single-digit bioprocessing growth and 30%+ equipment order growth.
  • Raised Full-Year Guidance: Core revenue growth now projected at 3-6%, with adjusted EPS guidance lifted to $8.35-$8.55 (up from prior ranges).
  • Masimo Acquisition Synergies: Deal expected to deliver $125 million in cost synergies and $50 million in revenue synergies, with high single-digit ROI by year 5.
  • Balanced Financial Position: Net debt/EBITDA at 2.5x post-acquisition, supported by $5+ billion annual free cash flow and $1.1 billion in Q1 free cash flow.

Q1 Financial Highlights

Sales of $6.00 billion matched expectations, with core revenue growth of just 0.5% year‑over‑year. Earnings per share at $2.06 beat analysts’ $1.94 forecast, reflecting strong cost controls and a healthy operating margin. Adjusted EBITDA grew 6.2%, reinforcing Danaher’s ability to translate revenue into profitability.

Segment Performance

Bioprocessing led the charge, with core revenue up 7% driven by high single‑digit growth in equipment orders and consumables. Life Sciences held steady with a 0.5% rise, while Diagnostics saw a 4% decline, largely due to a 25% drop in respiratory sales. Despite the dip, non‑respiratory segments posted solid gains.

Full‑Year Guidance

Danaher now targets core revenue growth of 3%‑6% for 2026 and has lifted adjusted diluted EPS guidance to $8.35‑$8.55, a 9% upside to prior forecasts. The company projects a mid‑single‑digit earnings growth in the first half, positioning it well for a 5% full‑year rise.

Strategic Acquisition: Masimo

The pending purchase of Masimo is expected to be accretive to EPS in the first full year post‑acquisition. Analysts anticipate high‑single‑digit ROI by year five, with $125 million in cost synergies and $50 million in revenue synergies, reinforcing Danaher’s acute‑care strategy.

Margin Outlook

Margins are expected to exhibit a typical seasonal step‑down from Q1 to Q2, yet the company’s focus on controlling raw material costs—particularly resins—has kept gross margins stable. AI‑driven efficiencies in bioprocessing are poised to further lift profitability.

Capital Allocation & Balance Sheet

Post‑Masimo, Danaher’s balance sheet remains strong with a Net Debt/EBITDA of 1.91 and free cash flow of $5 billion+. This liquidity cushion fuels ongoing M&A activity across Life Sciences, Diagnostics, and Bioprocessing, while maintaining a modest dividend yield of 0.37%.

Future Outlook

Looking ahead, Danaher anticipates 5% core growth in 2027, anchored by easing policy headwinds, accelerating China demand, and biotech funding translating into orders. Continued improvement in Life Sciences end markets and a robust respiratory season will be key to reaching the high end of guidance.

3. NewsRoom

Card image cap

Xylem Q1 Earnings Beat Estimates, Revenues Increase Y/Y

Apr -28

Source: zacks.com

Card image cap

Danaher Corporation $DHR Shares Purchased by AEGON ASSET MANAGEMENT UK Plc

Apr -26

Source: defenseworld.net

Card image cap

Calamos Advisors LLC Has $55.79 Million Stock Position in Danaher Corporation $DHR

Apr -25

Source: defenseworld.net

Card image cap

This Stock Is Up Over 52,700% Since Founding. Should Investors Buy After Its 36% Decline?

Apr -24

Source: fool.com

Card image cap

Arizona State Retirement System Sells 6,790 Shares of Danaher Corporation $DHR

Apr -24

Source: defenseworld.net

Card image cap

Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook

Apr -23

Source: reuters.com

Card image cap

Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

Apr -22

Source: prnewswire.com

Card image cap

Danaher Q1 2026 Earnings Update

Apr -22

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.40%)

6. Segments

Diagnostics

Expected Growth: 7.0%

The diagnostics segment is expected to grow slightly above the global average due to the increasing demand for healthcare services, technological advancements in diagnostic equipment, and the rising prevalence of diseases. This makes it a relatively stable and growing segment.

Life Sciences Excl. Biotechnology

Expected Growth: 6.0%

Life Sciences Excl. Biotechnology is expected to grow at a rate slightly below the global average. This is due to its dependence on research funding and the cyclic nature of research investments. However, the long-term trend towards more research and development in life sciences supports a relatively stable growth.

Biotechnology

Expected Growth: 8.0%

The biotechnology segment is expected to grow significantly above the global average. This is driven by the rapid advancements in biotechnology, increasing investment in biotech research, and the potential for breakthroughs in therapeutic and diagnostic areas.

7. Detailed Products

Life Sciences

Provides bioprocessing, discovery, and analytical solutions to help develop and manufacture biologics, vaccines, and medicines.

Diagnostics

Offers diagnostic instruments, reagents, and software to help diagnose and monitor diseases, including COVID-19.

Dental

Provides dental consumables, equipment, and digital dentistry solutions to help dental professionals improve patient care.

Environmental & Applied Solutions

Offers instruments, software, and services to help monitor and improve environmental quality, as well as provide solutions for industrial and applied markets.

8. Danaher Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Danaher Corporation operates in a industry with moderate threat of substitutes. The company's products and services are differentiated, but customers have some alternatives.

Bargaining Power Of Customers

Danaher Corporation's customers have low bargaining power due to the company's diversified product portfolio and strong brand recognition.

Bargaining Power Of Suppliers

Danaher Corporation's suppliers have moderate bargaining power due to the company's dependence on a few key suppliers for certain components.

Threat Of New Entrants

The threat of new entrants is low for Danaher Corporation due to the high barriers to entry in the industry, including significant capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high in Danaher Corporation's industry, with several established players competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 26.75%
Debt Cost 3.95%
Equity Weight 73.25%
Equity Cost 8.22%
WACC 7.08%
Leverage 36.53%

11. Quality Control: Danaher Corporation passed 7 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Agilent Technologies

A-Score: 5.2/10

Value: 2.0

Growth: 6.1

Quality: 7.8

Yield: 1.0

Momentum: 7.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Mettler-Toledo

A-Score: 5.2/10

Value: 3.0

Growth: 6.3

Quality: 7.1

Yield: 0.0

Momentum: 7.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
IDEXX Laboratories

A-Score: 5.1/10

Value: 0.0

Growth: 7.2

Quality: 8.6

Yield: 0.0

Momentum: 9.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
IQVIA

A-Score: 4.8/10

Value: 3.5

Growth: 6.9

Quality: 5.5

Yield: 0.0

Momentum: 7.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Thermo Fisher

A-Score: 4.8/10

Value: 1.7

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 7.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Danaher

A-Score: 4.3/10

Value: 1.7

Growth: 3.9

Quality: 6.8

Yield: 1.0

Momentum: 5.0

Volatility: 7.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

178.8$

Current Price

178.8$

Potential

-0.00%

Expected Cash-Flows